Ireland - English - HPRA (Health Products Regulatory Authority)

schwarz pharma limited - moexipril hydrochloride hydrochlorothiazide - tablets

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

intrapharm laboratories ltd - ziconotide acetate - solution for infusion - 100microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

intrapharm laboratories ltd - ziconotide acetate - solution for infusion - 100microgram/1ml

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - cream - see ingredients - each 1 g cream contains diflucortolone valerate 1 mg isoconazole nitrate 10 mg

European Union - English - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - ziconotide - injections, spinal; pain - analgesics - ziconotide is indicated for the treatment of severe, chronic pain in patients who require intrathecal (it) analgesia.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.125 mg

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.125 mg - digoxin is indicated for the treatment of mild to moderate heart failure in adults. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin is contraindicated in patients with: - ventricular fibrillation [see warnings and precautions (5.1)] - known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. digo

United States - English - NLM (National Library of Medicine)

precision dose, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml

United States - English - NLM (National Library of Medicine)

precision dose inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml - digoxin oral solution, usp is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin oral solution, usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. digoxin should not be used for the treatment of multifocal atrial tachycardia. allergy to digoxin is rare. digoxin is contraindicated in patients with a known hypersensitivity to digoxin or other forms of digitalis. digitalis glycosides, such as digoxin, are contraindicated in ventricula

United States - English - NLM (National Library of Medicine)

cardinal health - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.25 mg - lanoxin is indicated for the treatment of mild to moderate heart failure in adults. lanoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, lanoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin increases myocardial contractility in pediatric patients with heart failure. lanoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. lanoxin is contraindicated in patients with: lanoxin should be given to a pregnant woman only if clearly needed. it is also not known whether digoxin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. animal reproduction studies have not been conducted with digoxin. there are not enough data from clinical trials to determine